Dmytro Kharkov

NCCN event spotlights Atossa Therapeutics, Inc. breast cancer innovation

NCCN event spotlights Atossa Therapeutics, Inc. breast cancer innovation
Atossa unveils breast cancer research

Atossa Therapeutics, Inc. presented its latest developments in breast cancer research at the recent NCCN Annual Conference.

Dr. Sandra Hammer, PhD, delivered a detailed poster presentation covering new scientific advances and ongoing efforts in the field. The event provided an opportunity for Atossa Therapeutics, Inc. to share progress with industry peers and highlight cutting-edge innovation targeting breast cancer. Details shared at the conference are expected to inform further research collaborations and potential clinical applications.

Atossa Therapeutics has recently focused on scaling its precision endocrine therapies in oncology and Duchenne muscular dystrophy. The company has also presented preclinical data on muscle biomarker improvements in dystrophic mice using its (Z)-Endoxifen therapy at the MDA Conference earlier this year. These efforts highlight ongoing research initiatives beyond the current breast cancer developments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.